These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 7753453)

  • 1. Long-term low-dose calcitriol treatment in predialysis chronic renal failure: can it prevent hyperparathyroid bone disease?
    Nordal KP; Dahl E; Halse J; Attramadal A; Flatmark A
    Nephrol Dial Transplant; 1995; 10(2):203-6. PubMed ID: 7753453
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of secondary hyperparathyroidism of predialysis chronic renal failure with low doses of 1,25(OH)2D3: humoral and histomorphometric results.
    Coen G; Mazzaferro S; Bonucci E; Ballanti P; Massimetti C; Donato G; Landi A; Smacchi A; Della Rocca C; Cinotti GA
    Miner Electrolyte Metab; 1986; 12(5-6):375-82. PubMed ID: 3492662
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Calcitriol oral therapy for the prevention of secondary hyperparathyroidism in patients with predialytic renal failure.
    Panichi V; Andreini B; De Pietro S; Migliori M; Taccola D; Giovannini L; Ferdeghini M; Palla R
    Clin Nephrol; 1998 Apr; 49(4):245-50. PubMed ID: 9582556
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early therapy of renal bone disease with calcitriol: a prospective double-blind study.
    Baker LR; Abrams SM; Roe CJ; Faugere MC; Fanti P; Subayti Y; Malluche HH
    Kidney Int Suppl; 1989 Nov; 27():S140-2. PubMed ID: 2699994
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of long-term therapy with calcitriol in patients with moderate renal failure.
    Healy MD; Malluche HH; Goldstein DA; Singer FR; Massry SG
    Arch Intern Med; 1980 Aug; 140(8):1030-3. PubMed ID: 6893118
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Treatment of secondary hyperparathyroidisms of predialysis chronic renal failure with low doses of 1.25(OH)2D3].
    Kato N; Kasai K; Kawaguchi Y; Yamamoto H; Shigematu T; Sakai O
    Nihon Jinzo Gakkai Shi; 1995 Oct; 37(10):543-8. PubMed ID: 7474506
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Intravenous calcitriol in the treatment of the refractory secondary hyperparathyroidism of terminal chronic kidney failure].
    Almirall J; Torregrosa V; Arrizabalaga P; Cases A; Oliva J
    Med Clin (Barc); 1994 Mar; 102(9):325-8. PubMed ID: 8164458
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Four gland parathyroidectomy without reimplantation in patients with chronic renal failure.
    Saunders RN; Karoo R; Metcalfe MS; Nicholson ML
    Postgrad Med J; 2005 Apr; 81(954):255-8. PubMed ID: 15811891
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevention of metabolic bone disease in the pre-end-stage renal disease setting.
    Coburn JW; Elangovan L
    J Am Soc Nephrol; 1998 Dec; 9(12 Suppl):S71-7. PubMed ID: 11443772
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hyperparathyroidism in CAPD patients: therapy with pulse oral calcitriol.
    Juergensen PH; Finkelstein FO; Cooper K; Santacroce S; Kliger AS
    Adv Perit Dial; 1993; 9():257-9. PubMed ID: 8105938
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hyperparathyroidism in chronic renal failure and dialysis osteodystrophy.
    O'Riordan JL; Page J; Kerr DN; Walls J; Moorhead J; Crockett RE; Franz H; Ritz E
    Q J Med; 1970 Jul; 39(155):359-76. PubMed ID: 5478506
    [No Abstract]   [Full Text] [Related]  

  • 13. [Early treatment of secondary hyperparathyroidism in moderate renal insufficiency: low-phosphorus diet versus calcium carbonate].
    Aresté N; Amor J; Cambil T; Salgueira M; Sánchez-Palencia R; Páez C; Gómez O; Palma A
    Nefrologia; 2003; 23 Suppl 2():64-8. PubMed ID: 12778857
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Increased in vitro and ex vivo proliferation of erythroid precursors induced by calcitriol in chronic renal failure. Synergistic effect with rHuEPO].
    Aucella F; Gatta G; Vigilante M; Scalzulli RP; Mantuano S; Carotenuto M; Stallone C
    G Ital Nefrol; 2002; 19(2):137-42. PubMed ID: 12195411
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Medical parathyroidectomy. Its efficacy in treatment of lower maxillary brown tumor].
    Graciela Garcia M; Leanza H; Najun Zarazga C; Barreneche M
    Medicina (B Aires); 1996; 56(1):59-62. PubMed ID: 8734935
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Methods of correcting hyperphosphatemia in chronic renal failure and in dialysis (review)].
    Novikov AI
    Ter Arkh; 1997; 69(12):63-7. PubMed ID: 9503540
    [No Abstract]   [Full Text] [Related]  

  • 17. Oral paricalcitol for the treatment of secondary hyperparathyroidism in patients on hemodialysis or peritoneal dialysis.
    Ross EA; Tian J; Abboud H; Hippensteel R; Melnick JZ; Pradhan RS; Williams LA; Hamm LL; Sprague SM
    Am J Nephrol; 2008; 28(1):97-106. PubMed ID: 17914251
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the effects of daily and intermittent-dose calcitriol on serum parathyroid hormone and ionized calcium concentrations in normal cats and cats with chronic renal failure.
    Hostutler RA; DiBartola SP; Chew DJ; Nagode LA; Schenck PA; Rajala-Schultz PJ; Drost WT
    J Vet Intern Med; 2006; 20(6):1307-13. PubMed ID: 17186842
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low doses of calcitriol or calcium carbonate for the prevention of hyperparathyroidism in predialysis patients?
    Fournier A; Oprisiu R; Moriniere P; El Esper N
    Nephrol Dial Transplant; 1996 Jul; 11(7):1493-5. PubMed ID: 8815432
    [No Abstract]   [Full Text] [Related]  

  • 20. Opposite effects of calcitriol and paricalcitol on the parathyroid hormone-(1-84)/large carboxy-terminal-parathyroid hormone fragments ratio in patients with stage 5 chronic kidney disease.
    Monier-Faugere MC; Mawad H; Malluche HH
    Clin J Am Soc Nephrol; 2007 Nov; 2(6):1255-60. PubMed ID: 17942766
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.